U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H8ClF6NO2
Molecular Weight 383.673
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IMD-0354

SMILES

OC1=CC=C(Cl)C=C1C(=O)NC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F

InChI

InChIKey=CHILCFMQWMQVAL-UHFFFAOYSA-N
InChI=1S/C15H8ClF6NO2/c16-9-1-2-12(24)11(6-9)13(25)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6,24H,(H,23,25)

HIDE SMILES / InChI

Molecular Formula C15H8ClF6NO2
Molecular Weight 383.673
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.immd.co.jp/en/development.html | http://adisinsight.springer.com/drugs/800030091 | https://www.ncbi.nlm.nih.gov/pubmed/15194461

IMD-0354 is an inhibitor of IκB kinase-β (IKKβ) that blocks NF-κB nuclear translocation. Attenuates myocardial ischemia/reperfusion injury by decreasing expression of adhesion molecules ICAM-1 and P-selectin and inhibiting cytokine and chemokine production in cardiomyocytes. Induces G0/G1 cell cycle arrest and apoptosis in HMC-1 and breast cancer cells. IMD-0354 had been in phase I clinical trials for the treatment of atopic dermatitis.

Originator

Curator's Comment: http://adisinsight.springer.com/drugs/800030091

Approval Year

Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors.
2005 Mar 15
Thymic stromal lymphopoietin secretion of synovial fibroblasts is positively and negatively regulated by Toll-like receptors/nuclear factor-kappaB pathway and interferon-gamma/dexamethasone.
2007
Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms.
2007 Aug
Salicylanilide inhibitors of Toxoplasma gondii.
2012 Oct 11
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: http://www.immd.co.jp/en/development.html
1, 5, or 10 mg/kg intraperitoneal injection in a single bolus 5 min before the start of reperfusion.
Route of Administration: Other
IMD-0354 (0.1-1 uM) caused a significant reduction of both IL-1β (−77%) and MCP-1 (−76%) production in a concentration-dependent manner compared with vehicle-treated cells.
Substance Class Chemical
Created
by admin
on Sat Dec 16 07:58:30 GMT 2023
Edited
by admin
on Sat Dec 16 07:58:30 GMT 2023
Record UNII
76145IS906
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IMD-0354
Common Name English
3',5'-SALICYLOXYLIDIDE, 5-CHLORO-.ALPHA.,.ALPHA.,.ALPHA.,.ALPHA.',.ALPHA.',.ALPHA.'-HEXAFLUORO-
Systematic Name English
BENZAMIDE, N-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-5-CHLORO-2-HYDROXY-
Systematic Name English
N-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-5-CHLORO-2-HYDROXYBENZAMIDE
Systematic Name English
Code System Code Type Description
ChEMBL
CHEMBL3545089
Created by admin on Sat Dec 16 07:58:30 GMT 2023 , Edited by admin on Sat Dec 16 07:58:30 GMT 2023
PRIMARY
EPA CompTox
DTXSID50243248
Created by admin on Sat Dec 16 07:58:30 GMT 2023 , Edited by admin on Sat Dec 16 07:58:30 GMT 2023
PRIMARY
CAS
978-62-1
Created by admin on Sat Dec 16 07:58:30 GMT 2023 , Edited by admin on Sat Dec 16 07:58:30 GMT 2023
PRIMARY
PUBCHEM
5081913
Created by admin on Sat Dec 16 07:58:30 GMT 2023 , Edited by admin on Sat Dec 16 07:58:30 GMT 2023
PRIMARY
FDA UNII
76145IS906
Created by admin on Sat Dec 16 07:58:30 GMT 2023 , Edited by admin on Sat Dec 16 07:58:30 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY